Earnings Feed
Start Free
RECURSION PHARMACEUTICALS, INC.·4

Feb 19, 7:30 PM ET

Gibson Christopher 4

Research Summary

AI-generated summary

Updated

Recursion (RXRX) Director Christopher Gibson Sells 40,000 Shares

What Happened

  • Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), recorded a series of transactions in mid‑February 2026. On Feb 17, 27,265 shares were withheld to satisfy tax withholding for net‑settled restricted stock units (RSUs) — 27,265 shares x $3.49 = $95,155 (tax withholding).
  • On Feb 19 the filing shows conversion(s) of derivative securities and an open‑market sale: 40,000 shares were converted (reported at $0.00) and 40,000 shares were sold in the open market at $3.46 each, producing proceeds of $138,400. The sale was reported as executed under a Rule 10b5‑1 trading plan.

Key Details

  • Transaction dates & prices:
    • 2026-02-17: 27,265 shares withheld for tax @ $3.49 — $95,155 (code F; tax withholding for RSUs; footnote F1).
    • 2026-02-19: Conversion(s) of derivative security — 40,000 shares reported converted @ $0.00 (code C; see footnote F2 re: Class B → Class A conversion).
    • 2026-02-19: Open‑market sale — 40,000 shares @ $3.46 = $138,400 (code S; per a Rule 10b5‑1 plan — footnote F3).
  • Notable footnotes: F1 (net settlement/tax withholding), F2 (Class B convertible to Class A), F3 (10b5‑1 plan). Several other option/vesting footnotes appear in the filing but are not directly tied to these specific trades.
  • Shares owned after the transactions: Not specified in the excerpt provided.
  • Filing timeliness: Report filed 2026-02-19 for transactions on 2026-02-17 and 2026-02-19 — no late filing indicated in the provided data.

Context

  • The sequence (conversion of derivatives reported and immediate open‑market sale) resembles a conversion/exercise followed by a sale — i.e., shares converted from a derivative instrument and then sold. The Feb 17 RSU tax withholding is routine and not a market‑timing purchase signal.
  • The Feb 19 sale was executed under a pre‑existing 10b5‑1 plan (footnote F3), which is an automated plan that can reduce the appearance of timing‑based insider trades; such sales are often executed according to a preset formula rather than an insider’s ad‑hoc decision.